本帖最后由 老马 于 2013-3-13 13:43 编辑 " l% d& o6 e, M- |8 |1 A
4 U+ f" |; x1 h
健择(吉西他滨)+顺铂+阿瓦斯汀( i8 s6 H) ?; p ]. B
Gemzar +Cisplatin + Avastin4 [, r5 x, y6 F% g
http://annonc.oxfordjournals.org/content/21/9/1804.full
% }1 A' a. K! ^5 F. { YOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) - |* @# ]* f" r8 b$ ^7 S
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
/ {4 `) N" C4 z1 c4 tResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
$ `8 k. M0 L4 e2 V
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 893)
/ u) Q) {; ^5 ~$ M
华为网盘附件:% @ l( ]& @6 ]- o( `7 U
【华为网盘】ava.JPG
1 C: \2 l5 M# T: f) j! n4 X# { |